Pages-42-289-Section-5.2-listing-clinical-sites-cvs_Part-B.pdf

Pages-42-289-Section-5.2-listing-clinical-sites-cvs_Part-A.pdf

5.2-listing-of-clinical-sites-and-cvs-pages-1-41.pdf

5.2-tabular-listing.pdf

5.3.6-postmarketing-experience (2).pdf

BATES-93_tv.xpt

BATES-92_adc19ef-ve-cov-7pd2-wo-eval-sas.txt

PFIZER-.pdf

EUA_Fact_sheet_for_Recipients_Pediatric_5_11_yoa_Pfizer_BioNTech.pdf

PF00092_MTR_PFEM_EN.pdf

STN-125742_0_0-Section-2.5-Clinical-Overview.pdf

CRFs-for-site-1055.pdf

BATES-FDA-CBER-2021-5683-0002376_relrec.xpt

BATES-FDA-CBER-2021-5683-0002379_te.xpt

BATES-FDA-CBER-2021-5683-0002378_ta.xpt

BATES-FDA-CBER-2021-5683-0002377_supppr.xpt

BATES-FDA-CBER-2021-5683-0002375_addv-sas.txt

BATES_FDA_CBER_2021_5683_0002374_adc19ef_ve_sev_cov_7pd2_wo_eval.txt

BATES_FDA_CBER_2021_5683_0002373_adc19ef_ve_sev_cov_7pd2_eval_sas.txt

BATES_FDA_CBER_2021_5683_0002372_adc19ef_ve_cov_7pd2_eval_sas.txt

125742_S1_M1_debarment.pdf

125742_S1_M1_cover.pdf

125742_S1_M1_3674.pdf

125742_S1_M1_356h.pdf

125742_S1_M1_priority-review-request.pdf

CRFs-for-site-1128.pdf

CRFs-for-site-1096.pdf

CRFs-for-site-1081.pdf

Supplemental-Index-12-22-21.pdf

STN-125742_0_0-Section-2.7.3-Summary-of-Clinical-Efficacy.pdf